ElevateBio has been built to establish and leverage our expertise across multiple, integrated next-generation enabling technologies, including gene editing, iPSCs, and cell, protein, and vector engineering. With our highly innovative, next-generation enabling technologies under one roof and numerous experts in each field, we possess the ability to discover, develop, and manufacture therapeutics across a broad spectrum of cutting-edge cell and gene therapy technologies.
Highly innovative genome editing technology platform with RNA-guided nucleases, base editors, and PAM diversity
Setting a new standard with fully characterized, clinical-grade iPSC lines to accelerate the development of iPSC-derived immunotherapies and regenerative medicines
Platforms that enable the construction and scaling of cell and gene therapies, with a focus on immunotherapies
LifeEdit's highly innovative genome editing technology platform accelerates and broadens ElevateBio’s cell and gene therapy enabling technologies.
AlloVir is tackling one of the most challenging complications for patients who have undergone hematopoietic stem cell transplantation, fighting off life-threatening or life-altering viral diseases.
HighPass is taking a new approach, known as adoptive T-cell therapy, to research treatments and preventions for relapsing leukemia, which affects 25-50% of patients who have undergone HSCT to treat their cancer.
The strategic partnership gives MGH preferred access to ElevateBio’s BaseCamp research, process development, and manufacturing facility. ElevateBio will support a variety of MGH’s cell and gene therapy research programs. Our organizations will work together to identify cell and gene technologies and create therapeutics companies.
Collaborating with Boston Children’s Hospital to advance cell and gene therapy programs, ElevateBio is helping BHC researchers move their therapies through development more efficiently with access to our cutting-edge viral vector manufacturing facilities. This alliance will help accelerate the development of multiple cell and gene therapy platforms.